Enzo Lalli


Country: France


  1. Lalli E, Alonso J. Targeting DAX-1 in embryonic stem cells and cancer. Expert Opin Ther Targets. 2010;14:169-77 pubmed publisher
    ..The unusual structure and restricted expression pattern of DAX-1 may offer unique opportunities for drug discovery. ..
  2. Lalli E, Luconi M. The next step: mechanisms driving adrenocortical carcinoma metastasis. Endocr Relat Cancer. 2018;25:R31-R48 pubmed publisher
    ..We highlight perspectives of future research in the domain and possible new therapeutic avenues based on targeting factors having an important role in the metastatic process of ACC. ..
  3. Doghman Bouguerra M, Lalli E. ER-mitochondria interactions: Both strength and weakness within cancer cells. Biochim Biophys Acta Mol Cell Res. 2019;1866:650-662 pubmed publisher
    ..In this review, we highlight the central role of ER-mitochondria contact sites in tumorigenesis and focus on chemotherapeutic drugs or potential targets that act on MAM properties for new therapeutic approaches in cancer. ..
  4. Lalli E, Sasano H. 5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications. Horm Cancer. 2016;7:44-8 pubmed publisher
    ..These advances need now to be translated to create cellular and animal models more relevant to human disease in order to develop new and more effective diagnostic procedures and targeted therapies against this deadly malignancy. ..
  5. Lalli E, Barhanin J, Zennaro M, Warth R. Local Control of Aldosterone Production and Primary Aldosteronism. Trends Endocrinol Metab. 2016;27:123-131 pubmed publisher
    ..However, recent data show that the processes of nodule formation and aldosterone hypersecretion can be dissociated in pathological adrenals and suggest a model envisaging different molecular events for the pathogenesis of APA. ..
  6. Doghman Bouguerra M, Granatiero V, Sbiera S, Sbiera I, Lacas Gervais S, Brau F, et al. FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria. EMBO Rep. 2016;17:1264-80 pubmed publisher
    ..These results show that the ER-mitochondria uncoupling activity of FATE1 is harnessed by cancer cells to escape apoptotic death and resist the action of chemotherapeutic drugs. ..
  7. Ruggiero C, Doghman Bouguerra M, Ronco C, Benhida R, Rocchi S, Lalli E. The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. Mol Cell Endocrinol. 2018;474:57-64 pubmed publisher
    ..These results suggest that convergent activation of ER stress pathways by drugs acting via different mechanisms represents a valuable therapeutic option for ACC. ..
  8. Lalli E. Adrenocortical development and cancer: focus on SF-1. J Mol Endocrinol. 2010;44:301-7 pubmed publisher
    ..Here, I discuss recent data in the literature showing the implication of SF-1 and the importance of its dosage not only during development but also for adrenal cortex tumorigenesis in humans and mice...
  9. Lalli E, Doghman M, Latre De Late P, El Wakil A, Mus Veteau I. Beyond steroidogenesis: novel target genes for SF-1 discovered by genomics. Mol Cell Endocrinol. 2013;371:154-9 pubmed publisher
    ..The identification of the complete set of SF-1 target genes will be of great importance to open new avenues for therapeutic intervention in adrenal diseases...

More Information


  1. Ruggiero C, Doghman M, Lalli E. How genomic studies have improved our understanding of the mechanisms of transcriptional regulation by NR5A nuclear receptors. Mol Cell Endocrinol. 2015;408:138-44 pubmed publisher
    ..Those studies have allowed us to make a significant leap forward in our understanding of the mechanisms of transcriptional regulation of NR5A nuclear receptors in stem cells and cancer. ..
  2. Ruggiero C, Doghman Bouguerra M, Sbiera S, Sbiera I, Parsons M, Ragazzon B, et al. Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Sci Signal. 2017;10: pubmed publisher
    ..Because VAV2 is a druggable target, our findings suggest that blocking VAV2 may be a new therapeutic approach to inhibit metastatic progression in ACC patients. ..